The Hidden Profitability Drain of Incomparable Submission Data

Broker submissions that cannot be compared can destroy profitable growth because growth that is built on risk-selection decisions made without comparable data adds premium to the portfolio whose risk quality has not been assessed on the same basis as the existing portfolio, and whose pricing has not been calibrated against comparable risks from other brokers. The new business appears to contribute margin at the target combined ratio—the pricing model produced a technical price based on the submission data, and the technical price met the target—but the submission data was non-standard, the exposure was defined differently, the loss history was presented incompletely, and the pricing model's output was based on an input that did not describe the same risk as a standard submission would have. The growth appears profitable at the point of underwriting. The loss ratio that develops will reveal that the growth was not profitable, and the return on the capital deployed to fund the growth will be below the target. For CFOs, CUOs, and underwriting-performance analysts, incomparable submissions are a growth-quality problem: they fund growth whose profitability the inconsistent data has inflated.

Why does the profitability impact of incomparable submissions matter more now?

The profitability impact matters more now because the hardening market is increasing the premium available for growth, and the temptation to grow by accepting non-standard submissions is rising. When capacity is constrained and cedents are seeking coverage, brokers may submit risks in whatever format is fastest, and the reinsurer that does not enforce a submission standard may accept business whose data quality does not support the risk-selection decision. The enterprise risk framework that governs the portfolio's profitability depends on the data quality at the point of selection.

The second reason is the capital-allocation consequence: the CFO allocates capital to lines based on their expected return, and if the expected return for the growth segments is based on the pricing model's output—which used non-standard submission data—the expected return is overstated. The capital allocated to fund the growth earns a below-target return, and the aggregate ROE is reduced. The solvency relief that reinsurance provides is eroded by growth whose profitability the submission data has inflated.

The third reason is the compounding effect: as the growth funded by non-standard submissions accumulates, the portfolio's overall loss ratio rises, and the CUO's response—to tighten the underwriting guidelines, to increase the technical price—is a response to a profitability signal that was distorted by the data quality at the point of selection. The pricing of unknown risk is amplified when the data the pricing depends on is non-standard.

What goes wrong when incomparable-submission growth is not governed?

When incomparable-submission growth is not governed, five financial failures emerge: the margin on the growth segments deteriorates, the return on capital falls below the target, the earnings guidance is missed, the portfolio's composition is skewed, and the CUO discovers the profitability drag when the loss ratio develops.

1. How does the margin on the growth segments deteriorate?

The margin deteriorates because the pricing model produced a technical price based on submission data that understated the exposure, overstated the loss experience, or was defined differently than the standard, and the technical price was below the price that a standard submission would have produced. The growth was priced too low for the actual risk, and the margin is below the target.

2. Why does the return on capital fall below the target?

The return on capital falls because the capital allocated to the growth segments earns a lower margin than the allocation framework assumed, and the return on the allocated capital is below the target. The capital that was deployed to fund the growth produces a sub-target return.

3. How is the earnings guidance missed?

The CFO's guidance assumed the growth would contribute margin at the target combined ratio, and the actual margin contribution is lower due to the mispricing from the non-standard data. The guidance is missed by the amount of the margin drag.

4. How is the portfolio's composition skewed?

The portfolio's composition is skewed towards the brokers whose non-standard submissions were easier to underwrite—not because the risks were better but because the underwriting process was faster—and the skew is a concentration of mispriced risk.

5. How does the CUO discover the profitability drag?

The CUO discovers the drag when the loss ratio on the growth segments develops above the pricing expectation, and the post-hoc analysis traces the mispricing to the non-standard submission data that was used at the point of underwriting. The discovery is too late to recover the margin on the business already written.

Quantify the profitability drag of incomparable submissions before your growth strategy compounds it

Talk to Our Specialists

Visit Insurnest to learn how we help CFOs and CUOs measure the profitability impact of non-standard submission data.

What do CFOs and CUOs actually need from the incomparable-submission profitability analysis?

CFOs and CUOs need an analysis that compares the profitability of standard-submission-sourced business to non-standard-submission-sourced business, quantifies the margin drag, and builds the investment case for standardisation.

Pranav is the CFO of a multi-line reinsurer. The CUO reported that the property line's growth had exceeded the target, but the line's loss ratio was deteriorating. The investigation revealed that sixty percent of the new business was sourced from brokers whose submissions used non-standard exposure definitions, and the pricing model had produced technical prices that were five percent below the prices the standard-submission comparison would have indicated.

Pranav built the profitability analysis: the margin drag on the non-standard-sourced business was three points of combined ratio, and the drag was reducing the line's ROE by the same amount. He used the analysis to build the investment case for a submission-standardisation platform, and the board approved the investment.

That is what every CFO should be calculating: what is the margin drag of the growth that incomparable submissions are funding?

• A comparison of the loss ratio and ROE for standard-sourced versus non-standard-sourced business. "For each line, calculate the loss ratio and ROE for business sourced from standard submissions and from non-standard submissions, and the difference is the data-quality margin drag."
• A growth-quality metric that measures the proportion of new business sourced from standard submissions. "Track the percentage of new business that meets the submission-data standard, and include it in the CUO's portfolio-quality dashboard."
• A pricing-model sensitivity to the submission-data quality. "Run the pricing model on the standard data and on the original non-standard data for the same risk, and calculate the pricing difference attributable to the data quality."
• A capital-allocation adjustment for growth funded by non-standard submissions. "Apply a conservatism haircut to the expected return for growth segments where the submission-data quality is below the standard."
• An investment case for submission standardisation, based on the margin-drag quantification. "The investment cost versus the margin preserved by the standardisation, presented to the board as a capital-allocation decision."
• A board-level summary of the submission-data quality's profitability impact. "Present the margin-drag analysis, the growth-quality metric, and the investment case to the board."
• A broker-level profitability analysis that identifies which brokers' submissions are associated with the highest margin drag. "Identify the brokers whose submissions produce the largest pricing discrepancies, and prioritise them for the standardisation programme."
• A quarterly review of the submission-data quality's financial impact as part of the underwriting-performance governance.
• A target for the standard-submission proportion of new business, included in the CUO's performance objectives.
• An annual review of the standardisation programme's return on investment, comparing the margin preserved to the investment cost.

How can CFOs and CUOs build the incomparable-submission profitability analysis?

By directing the actuarial function to calculate the margin drag, defining the growth-quality metric, building the investment case, and reporting the impact to the board.

What does the profitability analysis deliver in practice?

A CFO who can quantify the margin the portfolio is losing to incomparable submissions, an investment case the board can evaluate, and a growth strategy whose profitability is based on comparable data.

Return to Pranav. Two years after the standardisation platform was deployed, the non-standard-submission proportion of new business has been reduced from sixty percent to fifteen percent, and the margin drag has been reduced proportionally. The board's quarterly review now includes the submission-data-quality metric.

The broader financial reflection is that growth is only profitable if the data on which the growth decisions are based is comparable across the sources of growth, and incomparable data is a growth-quality risk that erodes the return on the capital deployed. The CFO who quantifies the drag quantifies the cost of the data inconsistency.

Quantify the profitability drag of your incomparable submissions and build the investment case for standardisation

Talk to Our Specialists

Conclusion

For CFOs and CUOs, broker submissions that cannot be compared are a profitability drag on the portfolio's growth, and the CFO who quantifies the drag—through the margin comparison, the growth-quality metric, and the investment case—quantifies the cost of the data inconsistency and builds the case for the standardisation that eliminates it.

Frequently asked questions

How can incomparable broker submissions destroy profitable growth?

Growth driven by selecting risks on presentation quality adds premium whose risk was not assessed on the same basis, producing a loss ratio above the pricing expectation and eroding the margin on the growth.

What is the capital-consequence of growth built on incomparable submissions?

The capital allocated to growth earns a below-target return because the risks were mispriced due to inconsistent data, and the capital produces a lower return than the allocation framework assumed.

How can a CUO quantify the profitability impact of incomparable submissions?

By comparing the loss ratio of treaties won from standardised submissions to those from non-standard submissions, and calculating the margin difference multiplied by the premium volume.

What is the compounding effect of incomparable submissions on portfolio growth?

As the portfolio grows, the proportion from non-standard-submission brokers increases, and the margin drag compounds. The growth adds exposure to mispriced risk.

How does incomparable-submission growth affect the CFO's earnings guidance?

The guidance assumes growth contributes margin at target, but if growth is built on incomparable submissions producing a higher loss ratio, the actual contribution is lower.

What is the return-on-capital impact of incomparable-submission growth?

The ROE for growth segments falls below target, and the capital deployed to fund the growth earns a below-target return, reducing the portfolio's aggregate ROE.

How does the CFO present the incomparable-submission profitability impact to the board?

By including a comparison of loss ratio and ROE for treaties sourced from standardised versus non-standard submissions, showing the profitability drag.

What is the investment case for submission standardisation from a profitability perspective?

The investment has a return equal to the margin drag that non-standard submissions create, multiplied by the premium volume they represent.

About the author

Hitul Mistry is the Founder of Insurnest, an InsurTech company that engineers end-to-end technology exclusively for the insurance industry serving carriers, TPAs, MGAs, brokers, and reinsurers across India, the UAE, and the US. With more than a decade of insurance domain experience, he has built systems spanning underwriting automation, AI-powered underwriting intelligence, claims management, rating and quoting, broking and agency platforms, and reinsurance automation across Health/GMC, Group Life, Motor, P&C, and Reinsurance. Insurnest doesn't adapt generic software to insurance; it builds from the workflow up.

Connect with Hitul on LinkedIn.